A randomized phase II study (ALLG AMLM16) was conducted between Jan 2013 and May 2018 to determine whether sorafenib combined with intensive chemotherapy in newly diagnosed FLT3-ITD-mutated AML shows any survival benefit. The gene discussed is FLT3; the disease is acute myeloid leukemia.